178 related articles for article (PubMed ID: 11561873)
1. Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients--results of an epidemiological multicentre retrolective cohort study.
Beuth J; Ost B; Pakdaman A; Rethfeldt E; Bock PR; Hanisch J; Schneider B
Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S45-54. PubMed ID: 11561873
[TBL] [Abstract][Full Text] [Related]
2. Influence of a complementary treatment with oral enzymes on patients with colorectal cancers--an epidemiological retrolective cohort study.
Popiela T; Kulig J; Hanisch J; Bock PR
Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S55-63. PubMed ID: 11561874
[TBL] [Abstract][Full Text] [Related]
3. Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study.
Schumacher K; Schneider B; Reich G; Stiefel T; Stoll G; Bock PR; Hanisch J; Beuth J
Anticancer Res; 2003; 23(6D):5081-7. PubMed ID: 14981970
[TBL] [Abstract][Full Text] [Related]
4. Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.
Sakalová A; Bock PR; Dedík L; Hanisch J; Schiess W; Gazová S; Chabronová I; Holomanova D; Mistrík M; Hrubisko M
Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S38-44. PubMed ID: 11561871
[TBL] [Abstract][Full Text] [Related]
5. Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects.
Dale PS; Tamhankar CP; George D; Daftary GV
Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S29-34. PubMed ID: 11561869
[TBL] [Abstract][Full Text] [Related]
6. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
7. [Comparative epidemiological study in patients with rheumatic diseases illustrated in a example of a treatment with non-steroidal anti- inflammatory drugs versus an oral enzyme combination preparation].
Wittenborg A; Bock PR; Hanisch J; Saller R; Schneider B
Arzneimittelforschung; 2000 Aug; 50(8):728-38. PubMed ID: 10994157
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers.
Gujral MS; Patnaik PM; Kaul R; Parikh HK; Conradt C; Tamhankar CP; Daftary GV
Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S23-8. PubMed ID: 11561868
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
10. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany.
Vollbracht C; Schneider B; Leendert V; Weiss G; Auerbach L; Beuth J
In Vivo; 2011; 25(6):983-90. PubMed ID: 22021693
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
12. [Effects of proteolytic enzyme therapy with Wobe Mugos against chemotherapy-induced toxicity in breast cancer patients - results of a pilot study].
Petru E; Stranz B; Petru C
Wien Med Wochenschr; 2010 Nov; 160(19-20):513-6. PubMed ID: 20972712
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
14. The impact of patient compliance with adjuvant radiotherapy: a comprehensive cohort study.
Badakhshi H; Gruen A; Sehouli J; Budach V; Boehmer D
Cancer Med; 2013 Oct; 2(5):712-7. PubMed ID: 24403236
[TBL] [Abstract][Full Text] [Related]
15. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Wobe-Mugos E for reduction of oral mucositis after radiotherapy : results of a prospective, randomized, placebo-controlled, triple-blind phase III multicenter study.
Dörr W; Herrmann T;
Strahlenther Onkol; 2007 Mar; 183(3):121-7. PubMed ID: 17340069
[TBL] [Abstract][Full Text] [Related]
19. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
